Asia-Pacific Bladder Disorders Market, By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) - Industry Trends and Forecast to 2029.
Asia-Pacific Bladder Disorders Market Analysis and Insights
Bladder disorders are a group of disorders that can affect human life's daily activity. Some of the most common bladder disorders are Cystitis- in which the bladder is infected and causes inflammation. Urinary incontinence- loss of bladder control, interstitial cystitis- bladder pain and frequent, urgent urination, and the overactive bladder- a condition in which the bladder squeezes urine. Bladder disorders can affect the quality of life and cause other health problems. Health changes and issues, including nervous system and lifestyle factors, can cause or contribute to UI in men and women.
The most common bladder disorders are overactive bladder and UI. These problems are associated with the nervous system. Nerves carry messages from the brain to the bladder, indicating muscles contract or release. The brain decides the acceptable time to urinate, and UI can occur when there is a problem getting the message from the brain. Health changes and problems can lead the UI, including aging, bladder infection, constipation, diabetes, and overweight, among others
Asia-Pacific bladder disorders market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 13.1% in the forecast period of 2022 to 2029 and is expected to reach USD 5,280.11 million by 2029.
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable 2019-2014) |
Quantitative Units |
Revenue in USD Million |
Segments Covered |
By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) |
Countries Covered |
China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific |
Market Players Covered |
The major companies which are dealing in the market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences, among others. |
Market Definition of Asia-Pacific Bladder Disorders Market
Bladder related disorders include Cystitis - inflammation of the bladder, often from an infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first-line of pharmacotherapy in Overactive Bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Asia-Pacific Bladder Disorders Market Dynamics
Drivers
-
STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.
Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.
-
GROWING GERIATRIC POPULATION
Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.
According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with the Neurologic disorders such as dementia and in this age group OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.
-
RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
Nowadays, various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.
-
COMBINATION OF DIFFERENT TARGET THERAPIES
Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.
Opportunities
-
SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.
Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.
Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.
-
RISING DISEASE MANAGEMENT PROGRAMS
People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans.
Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.
Restraints/Challenges
However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.
This Asia-Pacific bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Post COVID-19 Impact on Asia- Pacific Bladder Disorders Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market
Recent Development
- In April, Axonics, Inc. announced the comprehensive launch of the Axonics F15 across the U.S., which is developing and commercializing novel products to treat bladder and bowel dysfunction. This launch by the company has increased its product portfolio, leading to increased sales and demand in the future.
Asia-Pacific Bladder Disorders Market Scope
Asia-Pacific bladder disorders market is segmented into type, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Cystitis
- Urinary Incontinence
- Overactive Bladder
- Interstitial Cystitis
- Bladder Cancer
On the basis of type, the Asia-Pacific bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, and bladder cancer.
Treatment type
- Surgery
- Medications
- Others
On the basis of product, the Asia-Pacific bladder disorders market is segmented into surgery, medication, and others.
End User
- Hospital
- Clinics
- Ambulatory Surgery centers
- Others
On the basis of end users, the Asia-Pacific bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others.
Distribution Channel
- Direct
- Retail
On the basis of distribution channel, the Asia-Pacific bladder disorders market is segmented into direct and retail.
Asia-Pacific Bladder Disorders Market Regional Analysis/Insights
Asia-Pacific bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.
Countries covered in this market are China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific.
China dominates the Asia-Pacific bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Bladder Disorders Market Share Analysis
Asia-Pacific bladder disorders market competitive landscape provides details about the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, and application dominance. The above data points are only related to the company’s focus on the Asia-Pacific bladder disorders market.
Some of the major players operating in the Asia-Pacific bladder disorders market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, APAC vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding of the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC BLADDER DISORDERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 ASIA PACIFIC BLADDER DISORDERS MARKET, PIPELINE ANALYSIS
5 ASIA PACIFIC BLADDER DISORDER MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS
6 ASIA PACIFIC BLADDER DISORDERS MARKET OVERVIEW
6.1 DRIVERS
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT
6.2.2 PRODUCTS RECALLS FROM MARKET
6.3 OPPORTUNITIES
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS
6.4.2 PATENT EXPIRY OF DRUGS
7 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVERACTIVE BLADDER
7.3 URINARY INCONTINENCE
7.4 CYSTITIS
7.5 INTERSTITIAL CYSTITIS
7.6 BLADDER CANCER
7.7 OTHERS
8 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATION
8.2.1 TOLTERODINE
8.2.2 MIRABEGRON
8.2.3 FESOTERODINE
8.2.4 OXYBUTYNIN
8.2.5 SOLIFENACIN
8.2.6 DARIFENACIN
8.2.7 TROSPIUM
8.2.8 OTHERS
8.3 SURGERY
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY
8.3.2 BLADDER REMOVAL
8.3.3 OTHERS
8.4 OTHERS
9 ASIA PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT
9.3 RETAIL
10 ASIA PACIFIC BLADDER DISORDERS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 OTHERS
11 ASIA PACIFIC BLADDER DISORDERS MARKET, BY GEOGRAPHY
11.1 ASIA-PACIFIC
11.1.1 CHINA
11.1.2 JAPAN
11.1.3 INDIA
11.1.4 AUSTRALIA
11.1.5 SOUTH KOREA
11.1.6 THAILAND
11.1.7 SINGAPORE
11.1.8 INDONESIA
11.1.9 MALAYSIA
11.1.10 VIETNAM
11.1.11 PHILIPPINES
11.1.12 REST OF ASIA-PACIFIC
12 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC. (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ASTELLAS PHARMA INC. (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 VIATRIS INC. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 AXONICS, INC. (2021)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BLUE WIND MEDICAL (2021)
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 COLOPLAST CORP. (2021)
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 LABORIE (2021)
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDTRONIC (2021)
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 PFIZER INC. (2021)
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 VALENCIA TECHNOLOGIES (2021)
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 SWATI SPENTOSE (2021)
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 UROVANT SCIENCES (2021)
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 ZYDUS GROUP (2021)
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tablas
TABLE 1 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 23 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 ASIA-PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 26 ASIA-PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 27 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 CHINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 CHINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 31 CHINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 32 CHINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 33 CHINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 CHINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 JAPAN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 JAPAN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 37 JAPAN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 JAPAN SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 39 JAPAN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 JAPAN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 INDIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 INDIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 43 INDIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 INDIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 INDIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 INDIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 AUSTRALIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 AUSTRALIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 49 AUSTRALIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 50 AUSTRALIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 AUSTRALIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 AUSTRALIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SOUTH KOREA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH KOREA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH KOREA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 56 SOUTH KOREA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 SOUTH KOREA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 SOUTH KOREA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 THAILAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 THAILAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 61 THAILAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 62 THAILAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 THAILAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 THAILAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 SINGAPORE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SINGAPORE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 67 SINGAPORE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 68 SINGAPORE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 SINGAPORE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 SINGAPORE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 INDONESIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 INDONESIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 73 INDONESIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 74 INDONESIA. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 INDONESIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 INDONESIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 MALAYSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 MALAYSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 79 MALAYSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 80 MALAYSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 81 MALAYSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 MALAYSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 83 VIETNAM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 VIETNAM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 85 VIETNAM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 86 VIETNAM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 87 VIETNAM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 88 VIETNAM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 89 PHILIPPINES BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 PHILIPPINES BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 91 PHILIPPINES MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 PHILIPPINES SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 PHILIPPINES BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 PHILIPPINES BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 REST OF ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA PACIFIC BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BLADDER DISORDERS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BLADDER DISORDERS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA PACIFIC BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE ASIA PACIFIC BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BLADDER DISORDERS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC BLADDER DISORDER MARKET
FIGURE 14 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, 2021
FIGURE 15 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 16 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 17 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 ASIA PACIFIC BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 23 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 24 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 25 ASIA PACIFIC BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, 2021
FIGURE 27 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 ASIA PACIFIC BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 ASIA-PACIFIC BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 31 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 32 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 35 ASIA PACIFIC BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.